Abstract

Psyllium seed polysaccharide was modified to investigate its use as multifunctional pharmaceutical excipient. The objective of this study was isolation of psyllium seed polysaccharide and crosslinking with acrylic acid using N,N-methylene bisacrylamide and its characterization. Acrylic acid was used as monomer and ammonium persulfate as initiator. A full factorial design was employed to optimize the crosslinking. The modified polysaccharide was characterized by FTIR, DSC, PXRD, loss on drying, pH, viscosity, micromeritics properties and swelling studies in 0.1N HCl, 0.5N NaOH, phosphate buffer pH 6.8. It was observed that swelling of crosslinked polysaccharide increased with decreased concentration of monomer and increasing concentration of crosslinker. Greater degree of grafting was observed with increase in crosslinker and monomer concentration. Dispersions of 1% w/v of PPS and APPS show pseudoplastic behavior. No clinical signs of toxicity were evident in repeat dose toxicity studies conducted in rats. Administration of up to 350mg/kg/day of APPS was well tolerated by the animals. Modification of psyllium via graft copolymerization and network formation with the crosslinker, improved the property profile and utility of psyllium polysaccharide. The modified polysaccharide can be used for designing controlled release drug delivery systems due to its swelling ability.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.